RAPPORT THERAPEUTICS INC (RAPP)
Health Care · biotechnology · NASDAQ
Rapport Therapeutics is a clinical-stage biotechnology company developing precision medicines for neurological disorders using its proprietary RAP platform to target specific neural circuits.
What RAPPORT THERAPEUTICS INC does
Rapport Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for neurological disorders. The company utilizes its proprietary RAP technology platform to discover and develop product candidates designed to target specific neural circuits associated with diseases of the nervous system.
Themes: neurology, precision medicine, drug discovery platform
Fundamentals
- Price$48.24 as of 2026-08-21 close
- Market cap$2.3B as of 2026-08-21
- 1-year return+223.1% 2025-08-21 close $14.93 → 2026-08-21 close $48.24
- P/En/a earnings data not available
- ROE-29.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta2.47 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How RAPP compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RAPP is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
56.2 #362 of 1,698 scored · #77 of 236 in Health Care
Trend 84th: a strong uptrend, with buyers in control; momentum 67th: over the past 3 months this stock beat the market by 28.3 percentage points; weakest is volume and participation 5th: trading volume is unusually light — only about 47% of its 30-day average.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How RAPPORT THERAPEUTICS INC looks technically
RAPPORT THERAPEUTICS INC (RAPP) is trading 44.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 3.3% below its all-time high. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 44.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +44.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $42.06 | $42.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $33.50 | $33.50 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 39.75. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 244 trading days ago — a "golden cross", a bullish long-term signal | 244 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control | 40.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($40.69 to $49.90) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 82.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.90 | $49.90 |
|---|---|---|
| From the 52-week high | it is 3.3% below its 52-week high (its highest price of the past year) | -3.3% |
| Above the 52-week low | it is 248.1% above its 52-week low (its lowest price of the past year) | +248.1% |
| Below the 52-week high | it is 3.3% below its highest point of the past year | 3.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $49.90 (set on 2026-08-19) | $49.90 |
| Given back of the 52-week move | over the past year its closes ranged ($14.24 to $49.07), and it has given back only a small part of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.43 to $27.55. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.4% |
| From the all-time high | it is 3.3% below its all-time high | -3.3% |
| Nearest price level | it is trading 8.8% above a support level at $43.99 — a price it turned at four times since 2026-06-30, most recently on 2026-07-28. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.8% |
| All-time low | its lowest closing price on record is $6.43 (set on 2025-03-04) | $6.43 |
| Above the all-time low | it is 650.2% above its all-time low | +650.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 85% of the past ~6 months) | 85th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.13 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.13 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $39.23 and $51.47 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $39.23 – $45.35 – $51.47 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges above its 200-day average price (44.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 4.6% since the prior reading | +4.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-07-28 has been "filled" 18 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 18 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.0 percentage points (the stock gained 13.3% while the market gained 2.3%) | +11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.3 percentage points (the stock gained 31.4% while the market gained 3.1%) | +28.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 51.0 percentage points (the stock gained 62.1% while the market gained 11.1%) | +51.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 202.6 percentage points (the stock gained 223.1% while the market gained 20.5%) | +202.6% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.6% of the share price. | +21.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 37% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $35.16 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +37.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $47.36 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +1.9% |
Price levels it has turned at before
RAPP last closed at $48.24 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $43.99 | Support | 8.8% below the last close | turned there four times · 2026-06-30 to 2026-07-28 |
| $40.81 | Support | 15.4% below the last close | turned there three times · 2026-04-17 to 2026-05-27 |
| $39.87 | Support | 17.4% below the last close | turned there twice · 2026-06-15 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $39.75.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $45.41 and $48.91 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $39.75.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Near the all-time high · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · all time high · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$62.05 range $50.00 – $80.00; median $59.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RAPP
- Consensus EPS estimate-$1.23 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the success of the RAP technology platform and its product candidates.","Uncertainty regarding regulatory approval processes and clinical trial outcomes.","Requirement for additional capital to fund research, development, and future commercialization activities."]
What changed in the latest 10-Q
AI-assisted comparison of RAPP's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited financial statements for year ended December 31, 2025 (newer filing, filed 2026-05-07)
- In December 2025, presented post-hoc analysis showing RAP-219 had consistent effects in first and second four-week segments with rapid onset of efficacy
- In April 2026, presented results from 8-week follow-up period showing sustained biomarker and clinical responses
- RAP-219 half-life revised estimate to 22 days compared to prior 14-day estimate
- Follow-up period showed even greater reductions in long episodes and clinical seizures than during 8-week treatment period in first four weeks (weeks 9-12)
- Clinically meaningful improvements over baseline continued through second four weeks of follow-up (weeks 13-16)
- FDA feedback from end-of-Phase 2 meeting received in December 2025 supporting advancement into two Phase 3 trials
- Phase 3 program in FOS on track to initiate in second quarter of 2026
- Plan to initiate Phase 3 trial in PGTCS in first half of 2027
- Bipolar mania Phase 2 topline results now expected in fourth quarter of 2026, ahead of previous guidance of first half of 2027
- Modified bipolar mania trial's statistical analysis plan and increased target enrollment
- Removed:
- Reference to audited financial statements for year ended December 31, 2024 (older filing, filed 2025-11-06)
- Reference to 'hippocampus and neocortex' replaced with 'neocortex and mesial temporal lobe' as regions where focal onset seizures originate
- References to 'focal onset seizures, bipolar disorder, and peripheral neuropathic pain' as evaluation indications changed to focus on 'focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania'
- Statement about four Phase 1 trials and details about January 2025 PET and MAD-2 results
- Expected presentation of additional efficacy analyses later in 2025
- Plan to hold end-of-Phase 2 meeting with FDA in fourth quarter of 2025
- Expected Phase 3 initiation in third quarter of 2026
- Bipolar mania trial currently enrolling patients with topline results expected in first half of 2027
- Discussion of peripheral neuropathic pain program and clinical hold on DPNP IND
- Discussion of next steps for neuropathic pain program expected to be determined in first quarter of 2026
- Reworded:
- Changed from 'discovering and developing' to 'dedicated to the discovery and development of'
- Removed '('FOS')' abbreviation on first mention; added explicit abbreviation '('FOS')' in newer context about focal onset seizures
- Changed from describing TARPγ8 expression locations as 'hippocampus and neocortex' to 'neocortex and mesial temporal lobe'
- Changed from 'dosing regimens' to 'alternative dosing regimens'
- Changed from 'human positron emission tomography' to shortened reference to 'positron emission tomography'
- Replaced detailed Phase 1 trial summary with simpler statement 'Several Phase 1 trials in RAP-219 have been conducted'
- Changed 'drug-resistant focal onset seizures' to abbreviation 'drug-resistant FOS' throughout newer version
- Added 'primary generalized tonic-clonic seizures' ('PGTCS') as separate indication expansion rather than grouped with other indications
- Notes:
- Newer filing text appears truncated at end ('potentially be c'), limiting full comparison of final paragraphs
- Older filing text also appears truncated ('Third-party genetic data s'), limiting full comparison of final sections
Risk Factors
- Added:
- Added bullet point in forward-looking statements: 'our ability to achieve any milestones in connection with our license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd.' (filed 2026-05-07)
- Expanded Risk Factors page count from 39 to 40 pages (filed 2026-05-07)
- Expanded Item 2 page reference from 93 to 99 (filed 2026-05-07)
- Expanded Item 3 page reference from 93 to 99 (filed 2026-05-07)
- Expanded Item 4 page reference from 93 to 99 (filed 2026-05-07)
- Expanded Item 5 page reference from 93 to 99 (filed 2026-05-07)
- Expanded Item 6 page reference from 94 to 100 (filed 2026-05-07)
- Expanded Signatures page reference from 95 to 101 (filed 2026-05-07)
- Removed:
- Removed specific reference to 'including our ability to resolve the U.S. Food and Drug Administration's clinical hold on our Phase 2 proof-of-concept trial of RAP-219 for the treatment of diabetic peripheral neuropathic pain' from forward-looking statements bullet (filed 2025-11-06)
- Removed abbreviations 'FDA', 'EMA', and 'MHRA' in parentheses in the regulatory approval bullet point, now referenced without abbreviations (filed 2026-05-07)
- Reworded:
- Changed 'the initiation, timing, progress, and results of our research and development programs, preclinical studies and clinical trials, including our ability to resolve the U.S. Food and Drug Administration's clinical hold on our Phase 2 proof-of-concept trial of RAP-219 for the treatment of diabetic peripheral neuropathic pain' to 'the initiation, timing, progress, and results of our research and development programs, preclinical studies and clinical trials' - removed specific clinical hold reference (filed 2026-05-07)
- Changed regulatory authorities reference from 'Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), Medicines and Healthcare products Regulatory Agency ("MHRA")' to 'Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency' - removed parenthetical abbreviations (filed 2026-05-07)
- Notes:
- The newer filing text provided appears truncated at 'We are dependent on a third party having accurately generated, collected, interpreted and repor', limiting full assessment of Risk Factors section content changes
- Page number changes may reflect document pagination differences rather than substantive content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 15 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 7 sells ($3M) — 1 selling insider
- Last 90 days0 buys · 15 sells ($4M) — 2 selling insiders
- Last 180 days0 buys · 21 sells ($39M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RAPP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding RAPP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,444,146
- Reported value $326,797,328
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RAPP had 2,248,235 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RAPP had 4.69% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.51 days to cover at the same settlement.
- Reported short interest (shares) 2,248,235
- Short interest (% of shares outstanding) 4.69%
- Prior settlement (shares) 2,690,734
- Reported change -16.45%
- Days to cover (reported) 7.51
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Sage Therapeutics
- Acadia Pharmaceuticals (ACAD)
- Neurocrine Biosciences (NBIX)
- Axsome Therapeutics (AXSM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RAPP vs…
RAPPORT THERAPEUTICS INC is found in…
Frequently asked questions
What does RAPPORT THERAPEUTICS INC (RAPP) do?
Rapport Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for neurological disorders. The company utilizes its proprietary RAP technology platform to discover and develop product candidates designed to target specific neural circuits associated with diseases of the nervous system.
What sector is RAPPORT THERAPEUTICS INC (RAPP) in?
RAPPORT THERAPEUTICS INC (RAPP) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are RAPPORT THERAPEUTICS INC's (RAPP) competitors?
Notable peers of RAPPORT THERAPEUTICS INC (RAPP) include Biogen, Sage Therapeutics, Acadia Pharmaceuticals, Neurocrine Biosciences and Axsome Therapeutics. This peer set is informational only — not financial advice.
Is RAPPORT THERAPEUTICS INC (RAPP) overbought or oversold right now?
RAPPORT THERAPEUTICS INC (RAPP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RAPP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.